JPS634527B2 - - Google Patents
Info
- Publication number
- JPS634527B2 JPS634527B2 JP16299079A JP16299079A JPS634527B2 JP S634527 B2 JPS634527 B2 JP S634527B2 JP 16299079 A JP16299079 A JP 16299079A JP 16299079 A JP16299079 A JP 16299079A JP S634527 B2 JPS634527 B2 JP S634527B2
- Authority
- JP
- Japan
- Prior art keywords
- aqueous humor
- artificial aqueous
- sodium
- ions
- artificial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000001742 aqueous humor Anatomy 0.000 claims description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- -1 citrate ions Chemical class 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 17
- 210000004087 cornea Anatomy 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003855 balanced salt solution Substances 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 230000002262 irrigation Effects 0.000 description 3
- 238000003973 irrigation Methods 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 239000013010 irrigating solution Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RGCKGOZRHPZPFP-UHFFFAOYSA-N Alizarin Natural products C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940113601 irrigation solution Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は眼内潅流液として、あるいは眼球、眼
組織たとえば角膜の洗浄液や保存液として使用さ
れる人工房水の製造法に関する。
近年、白内障、虹彩、硝子体および角膜移殖な
どの眼科手術の進歩と普及にともないたとえば手
術時に眼内へ潅流するための人工房水が要求され
ている。それは眼内組織に障碍を与えるものであ
つてはならない。もし眼内組織に障碍を与えると
術後の経過を悪くし、また角膜混濁、緑内障、網
膜炎などが併発する危険性がある。
人工房水はできるだけ自然の房水に近い組成を
もつことが望ましいが、現在眼内潅流に用いられ
ているものは生理食塩水、乳酸リンゲル液などが
主で、さらにBSS(Balanced salt solution)が
開発途上にある状態である。これらのものは製剤
としては安定であると考えられるが、細胞に必要
なブドウ糖を欠き、眼内潅流液に必要とされる炭
酸水素イオンを欠いている。
先にメリアムとキンゼイは房水に近いイオン組
成にブドウ糖および乳酸を加えた組織培養液を発
表しているが、このものは加熱滅菌により、また
は数日間室温で放置することにより白色沈澱物を
生ずるので人工房水としては好ましくない。そこ
で本発明者らはこの処方から沈澱の原因と考えら
れるリン酸ナトリウムを除いてみたが沈澱の生成
は防止できなかつた。そして、この沈澱物を検討
した結果、それが塩基性炭酸カルシウムおよび塩
基性炭酸マグネシウムの混合物であることを見出
した。
この沈澱を防止するために生体に無害の陰イオ
ンを添加して試験したところ、乳酸、酢酸、グル
タミン酸、グルコン酸イオンなどは効果が無かつ
たが、意外にもクエン酸イオンの添加により問題
の沈澱物の生成を完全に防止できることを発見し
た。
本発明はこれらの知見に基づくもので、カルシ
ウムおよびマグネシウムイオンを含む人工房水の
製造において、炭酸水素およびクエン酸イオンを
添加することを特徴とする安定な人工房水の製造
法である。
炭酸水素イオンは、通常無害な水溶性塩、たと
えばナトリウム塩、カリウム塩の形で人工房水の
組成中に加えられる。
クエン酸イオンは、クエン酸またはその無害な
水溶性塩、たとえばナトリウム塩、カリウム塩ま
たはアンモニウム塩、好ましくはナトリウム塩、
カリウム塩の形で人工房水組成中に加えられう
る。
遊離のクエン酸をクエン酸イオン供給源として
加える場合は人工房水組成物水溶液のPHが低下す
るので、最終的にPHを人工房水に適した6.5―
7.5、好ましくは7―7.5に調整するのがよい。そ
のPH調整剤としては一般にナトリウム、カリウ
ム、リチウム、アンモニウムの水酸化物、炭酸塩
類が用いられるが、好ましいのはナトリウム、カ
リウムの水酸化物、炭酸塩類である。
クエン酸イオンは、人工房水中におけるカルシ
ウムとマグネシウムの各イオン濃度の和と等モル
以上になるように加えるのがよく、このような割
合でクエン酸イオンを加えても人工房水中におい
てクエン酸カルシウムまたはマグネシウムなどに
起因する沈澱を生ずることはない。
実際上、クエン酸イオンは、クエン酸またはク
エン酸塩として、人工房水中に0.07―0.2(W/
V)%加えられゝば充分である。
かくして得られる本発明の人工房水は、加熱滅
菌や長期の保存においても沈澱を析出せず、また
PHの変動もなく、きわめて安定である。
本発明の人工房水は眼内潅流液として用いられ
るばかりでなく、眼球や眼組織の洗浄や保存用に
も用いることができる。
以下実施例により本発明をさらに具体的に説明
する。
実施例 1
塩化ナトリウム 6.60g
塩化カリウム 0.36g
塩化カルシウム(2水塩) 0.18g
硫酸マグネシウム(7水塩) 0.30g
炭酸水素ナトリウム 2.10g
クエン酸ナトリウム(2水塩) 1.00g
酢酸ナトリウム(3水塩) 0.60g
ブドウ糖 1.50g
以上を滅菌精製水約900mlに溶かし、これに10
(W/V)%塩酸を加えてPH7.2に調整したのち、
滅菌精製水を全量1000mlになるまで加えて加圧無
菌濾過する。これを20mlアンプルおよび、500ml
のバイアルびんに充填し、熔封または密栓したの
ち加熱滅菌する。浸透圧は280〜300mOsmであ
る。
<径時変化試験>
40°、6ケ月および室温24ケ月の径時変化を調
べたが外観変化およびPHの変動は見られなかつ
た。
<薬理試験>
1 大鳥の方法に従い上記の人工房水、生理食塩
水、乳酸リンゲル液およびBSSの各々400mlに
家免左眼角膜を各々1枚づつ入れて37℃で培養
を行なつた。観察項目として、培養角膜の含水
量およびナトリウム、カリウム、塩素の各イオ
ンの変動をそれぞれ正常右眼角膜を対照として
測定した。その結果、本発明の眼内潅流液では
8、16時間の培養でも正常角膜とほとんど差が
なかつた。また、これに対し、生理食塩水、乳
酸リンゲン液およびBSSでは個々の差はあるが
8時間培養では正常値と比較して差が見られ、
16時間ではさらにその差がはつきり表われた
(表1)。なお、生理食塩水では、カリウムイオ
ンが含まれてないため8時間培養では角膜中の
カリウムイオンは減少していた。
2 Dikstein and Mauriceの方法に従い家免角
膜を角膜固定装置に装着し、35℃の保温条件下
で角膜内皮側(前房側)を毎時約2mlの流速で
上記眼内潅流液、生理食塩水、乳酸リンゲル液
またはBSSで3時間まで潅流させながら顕微鏡
下で角膜中央部の厚さを測定した。さらに、測
定後、角膜内皮細胞の状態を見るためPrince
and Peymanの方法によりトリパンブルーとア
リザリンレツトSで染色し、顕微鏡で観察し
た。その結果、本発明の人工房水で潅流を行な
つた場合、その角膜の厚さは3時間で15〜20μ
しか増加しなかつたのに対し、生理食塩水では
約350μ、乳酸リンゲル液では約150μ、BSSで
は約90μ増加した。また、潅流後の角膜内皮細
胞の観察では本発明の人工房水の場合、細胞の
形がほゞ正常な6角形に保たれていたのに対
し、他の溶液では程度の差はあるが、角が取れ
て丸くなつており、また、細胞脱落した部分が
認められ、生理食塩水の場合は特に顕著であつ
た。
以上の薬効薬理試験をまとめると本発明の人工
房水は他剤と比べて非常にすぐれており、人工房
水として満足すべきものである。
The present invention relates to a method for producing an artificial aqueous humour, which is used as an intraocular irrigating solution, or as a cleaning solution or preservation solution for the eyeball, ocular tissue, such as the cornea. In recent years, with the progress and spread of ophthalmic surgeries such as cataract, iris, vitreous, and corneal transplants, there has been a demand for artificial aqueous humor for perfusing the eye during surgery, for example. It must not cause any damage to intraocular tissues. If the intraocular tissue is damaged, the postoperative course will worsen, and there is a risk of complications such as corneal clouding, glaucoma, and retinitis. It is desirable for artificial aqueous humor to have a composition as close as possible to natural aqueous humor, but currently the main ones used for intraocular irrigation are physiological saline and lactated Ringer's solution, and BSS (Balanced salt solution) has also been developed. It is still in progress. Although these are considered stable as formulations, they lack the glucose needed by cells and the bicarbonate ions needed for intraocular irrigation fluids. Merriam and Kinsey previously published a tissue culture medium with an ionic composition similar to that of aqueous humor with the addition of glucose and lactic acid, but this produces a white precipitate when sterilized by heat or left at room temperature for several days. Therefore, it is not preferred as an artificial aqueous humor. Therefore, the present inventors tried removing sodium phosphate, which is thought to be the cause of precipitation, from this formulation, but the formation of precipitation could not be prevented. After examining this precipitate, they discovered that it was a mixture of basic calcium carbonate and basic magnesium carbonate. In order to prevent this precipitation, we tested adding anions that are harmless to living organisms, and found that lactic acid, acetic acid, glutamic acid, gluconate ions, etc. had no effect, but surprisingly, the addition of citrate ions solved the problem. It has been discovered that the formation of precipitates can be completely prevented. The present invention is based on these findings, and is a method for producing stable artificial aqueous humor, which is characterized by adding hydrogen carbonate and citrate ions in the production of artificial aqueous humor containing calcium and magnesium ions. Bicarbonate ions are usually added to the composition of artificial aqueous humor in the form of harmless water-soluble salts, such as sodium salts, potassium salts. The citric acid ion can be citric acid or a harmless water-soluble salt thereof, such as a sodium salt, a potassium salt or an ammonium salt, preferably a sodium salt;
It can be added to the artificial aqueous humor composition in the form of potassium salts. When free citric acid is added as a citrate ion source, the pH of the artificial aqueous humor composition aqueous solution decreases, so the final pH is adjusted to 6.5, which is suitable for artificial aqueous humor.
It is best to adjust it to 7.5, preferably 7-7.5. As the pH adjuster, hydroxides and carbonates of sodium, potassium, lithium, and ammonium are generally used, and preferred are hydroxides and carbonates of sodium and potassium. It is best to add citrate ions in an amount equal to or more than the sum of the concentrations of calcium and magnesium ions in the artificial aqueous humor. Also, precipitation caused by magnesium etc. does not occur. In practice, citrate ion is present in the aqueous humor as citric acid or citrate at 0.07-0.2 (W/
V)% is sufficient. The artificial aqueous humor of the present invention thus obtained does not precipitate even during heat sterilization or long-term storage, and
It is extremely stable with no pH fluctuations. The artificial aqueous humor of the present invention can be used not only as an intraocular irrigation fluid, but also for cleaning and preserving eyeballs and ocular tissues. The present invention will be explained in more detail with reference to Examples below. Example 1 Sodium chloride 6.60g Potassium chloride 0.36g Calcium chloride (dihydrate) 0.18g Magnesium sulfate (7hydrate) 0.30g Sodium hydrogen carbonate 2.10g Sodium citrate (dihydrate) 1.00g Sodium acetate (trihydrate) ) Dissolve 0.60g of glucose or more than 1.50g in approximately 900ml of sterile purified water, add 10g of glucose to this
After adjusting the pH to 7.2 by adding (W/V)% hydrochloric acid,
Add sterile purified water to a total volume of 1000ml and filter aseptically. Add this to 20ml ampoule and 500ml
Fill it into a vial, seal it or seal it, and heat sterilize it. Osmotic pressure is 280-300mOsm. <Time change test> Time change was examined at 40° for 6 months and at room temperature for 24 months, but no change in appearance or PH was observed. <Pharmacological test> 1 According to Otori's method, one cornea of the left eye was placed in 400 ml each of the artificial aqueous humor, physiological saline, lactated Ringer's solution, and BSS and cultured at 37°C. As observation items, changes in water content and sodium, potassium, and chlorine ions in the cultured cornea were measured using the normal cornea of the right eye as a control. As a result, there was almost no difference between the intraocular irrigation solution of the present invention and normal cornea even after 8 and 16 hours of culture. In contrast, although there are individual differences between physiological saline, lactated Ringen's solution, and BSS, differences were observed in 8-hour culture compared to normal values.
At 16 hours, the difference was even more pronounced (Table 1). Note that since physiological saline does not contain potassium ions, potassium ions in the cornea decreased after 8 hours of culture. 2. According to the method of Dikstein and Maurice, the isolated cornea was attached to a corneal fixation device, and the above intraocular irrigating solution, physiological saline, Central corneal thickness was measured under a microscope while perfused with lactated Ringer's solution or BSS for up to 3 hours. Furthermore, after the measurement, Prince
The cells were stained with trypan blue and Alizarin Ret S according to the method of John and Peyman, and observed under a microscope. As a result, when perfusion was performed with the artificial aqueous humor of the present invention, the thickness of the cornea decreased by 15 to 20 μm in 3 hours.
In contrast, it increased by about 350μ with physiological saline, about 150μ with lactated Ringer's solution, and about 90μ with BSS. In addition, observation of corneal endothelial cells after perfusion showed that in the case of the artificial aqueous humor of the present invention, the cell shape was maintained in a normal hexagonal shape, whereas in other solutions, although there were differences in degree, The corners were rounded and there were areas where cells had fallen off, which was especially noticeable in the case of physiological saline. To summarize the above pharmacological tests, the artificial aqueous humor of the present invention is very superior to other drugs and is satisfactory as an artificial aqueous humor.
【表】
実施例 2
塩化ナトリウム 6.60g
塩化カリウム 0.36g
塩化カルシウム(2水塩) 0.18g
硫酸マグネシウム(7水塩) 0.30g
炭酸水素ナトリウム 2.10g
クエン酸 0.80g
酢酸ナトリウム(3水塩) 0.60g
ブドウ糖 1.5g
以上を滅菌精製水約900mlに溶かし、これに1
規定の水酸化ナトリウム液を加えてPH7.2に調整
し、さらに滅菌精製水を加えて全量1000mlとす
る。これを加圧無菌濾過後、20mlのアンプルおよ
び500mlのバイヤルびんにそれぞれ充填し、熔閉
または密栓後、加熱滅菌する。
安定性については40℃、6ケ月および室温24ケ
月の径時変化を調べたが外観変化およびPHの変動
は見られなかつた。
実施例 3
塩化ナトリウム 7.00g
塩化カルシウム(2水塩) 0.18g
硫酸マグネシウム(7水塩) 0.30g
炭酸水素ナトリウム 2.10g
クエン酸 1.00g
酢酸ナトリウム(3水塩) 0.60g
ブドウ糖 1.50g
以上を滅菌精製水約900mlに溶かし、これに炭
酸カリウムを加えてPH7.2に調整したのち、滅菌
精製水を全量1000mlになるまで加えて加圧無菌濾
過する。これを20mlのアンプルおよび、500mlの
バイヤルびんに充填し、熔封または密栓したの
ち、加熱滅菌する。
安定性については40゜、6ケ月、室温24ケ月の
径時変化を調べたが外観変化およびPHの変動は見
られなかつた。
また、実験例2,3ともに実験例1とほとんど
同様の薬効薬理を示した。[Table] Example 2 Sodium chloride 6.60g Potassium chloride 0.36g Calcium chloride (dihydrate) 0.18g Magnesium sulfate (7hydrate) 0.30g Sodium hydrogen carbonate 2.10g Citric acid 0.80g Sodium acetate (trihydrate) 0.60g Dissolve 1.5g or more of glucose in approximately 900ml of sterile purified water, add 1.
Add the specified sodium hydroxide solution to adjust the pH to 7.2, and then add sterile purified water to make a total volume of 1000 ml. After sterile filtration under pressure, this is filled into 20 ml ampoules and 500 ml vials, which are then melted or sealed and sterilized by heating. Regarding stability, changes over time were investigated at 40°C for 6 months and at room temperature for 24 months, but no changes in appearance or pH were observed. Example 3 Sodium chloride 7.00g Calcium chloride (dihydrate) 0.18g Magnesium sulfate (7hydrate) 0.30g Sodium hydrogen carbonate 2.10g Citric acid 1.00g Sodium acetate (trihydrate) 0.60g Glucose 1.50g Sterilize and purify the above Dissolve in approximately 900 ml of water, add potassium carbonate to adjust the pH to 7.2, add sterilized purified water to a total volume of 1000 ml, and filter aseptically under pressure. This is filled into 20 ml ampoules and 500 ml vials, sealed or sealed, and then heat sterilized. As for stability, changes over time were investigated at 40° for 6 months and at room temperature for 24 months, but no changes in appearance or pH were observed. Moreover, both Experimental Examples 2 and 3 showed almost the same medicinal efficacy and pharmacology as Experimental Example 1.
Claims (1)
人工房水の製造において、炭酸水素およびクエン
酸イオンを添加することを特徴とする安定な人工
房水の製造法。 2 人工房水がブドウ糖を含む特許請求の範囲第
1項記載の製造法。 3 人工房水のPHが6.5―7.5、望ましくは7―7.5
である特許請求の範囲第1項又は第2項記載の製
造法。[Scope of Claims] 1. A method for producing stable artificial aqueous humor, which comprises adding hydrogen carbonate and citrate ions in the production of artificial aqueous humor containing calcium and magnesium ions. 2. The manufacturing method according to claim 1, wherein the artificial aqueous humor contains glucose. 3 PH of artificial aqueous humor is 6.5-7.5, preferably 7-7.5
The manufacturing method according to claim 1 or 2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16299079A JPS5686115A (en) | 1979-12-14 | 1979-12-14 | Preparation of artificial aqueous humor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16299079A JPS5686115A (en) | 1979-12-14 | 1979-12-14 | Preparation of artificial aqueous humor |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5686115A JPS5686115A (en) | 1981-07-13 |
JPS634527B2 true JPS634527B2 (en) | 1988-01-29 |
Family
ID=15765106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP16299079A Granted JPS5686115A (en) | 1979-12-14 | 1979-12-14 | Preparation of artificial aqueous humor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5686115A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3228699B2 (en) * | 1997-04-22 | 2001-11-12 | 株式会社オフテクス | Perfusion solution for eye surgery |
-
1979
- 1979-12-14 JP JP16299079A patent/JPS5686115A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5686115A (en) | 1981-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4819617A (en) | Viscoelastic material for ophthalmic surgery | |
US4443432A (en) | Ophthmalic irrigating solution | |
JP4146910B2 (en) | Ophthalmic formulation of sodium hyaluronate active ingredient for ophthalmic surgery | |
JP3795105B2 (en) | Ophthalmic preparations for use as artificial tears | |
US5409904A (en) | Hyaluronic acid compositions and methods | |
US4238482A (en) | Intraocular infusion irrigation solution and method | |
JPH0455070B2 (en) | ||
US4837021A (en) | Two part tissue irrigating solution | |
CN111107838B (en) | Eye drop composition containing rebamipide for treating dry eye and solubilization and stabilization method thereof | |
CN100522162C (en) | New pranoprofen eye drops and its preparation method | |
CN101972224B (en) | Eye in-situ gel | |
US5221537A (en) | Tissue irrigating solutions | |
AU1399695A (en) | Improved intraocular irrigating solution containing non-steroidal antiinflammatory agent | |
JP4033510B2 (en) | Ophthalmic pharmaceutical composition containing trehalose | |
JPS634527B2 (en) | ||
WO2009086073A1 (en) | Stabilized glycerophosphate-containing surgical irrigating solution | |
CN105749360B (en) | A kind of composition and the preparation method and application thereof for protecting cornea | |
JP3228699B2 (en) | Perfusion solution for eye surgery | |
RU2098100C1 (en) | Irrigation fluid for ophthalmological operations | |
US5500445A (en) | Intraocular irrigating and enucleated eyeball preservative composition | |
KR100550023B1 (en) | Perfusion liquid preparations for ophthalmic operations | |
RU2286170C1 (en) | Ophthalmic film | |
US5380537A (en) | Single irrigating solution used in ocular therapy for the endothelium protection and cornea preservation | |
CN110200904A (en) | A kind of drop intraocular pressure sustained release eye drop composition and preparation method thereof | |
RU2284181C2 (en) | Pharmaceutical composition for prophylaxis of ophthalmological infections |